Deepa Rangachari

发表

Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors

D. Leaf, D. Iberri, Douglas B. Johnson, 2019, American journal of hematology.

Pulmonary Resection for Isolated Pancreatic Adenocarcinoma Metastasis: an Analysis of Outcomes and Survival

J. Cameron, T. Pawlik, R. Hruban, 2011, Journal of Gastrointestinal Surgery.

In search of goldilocks: the quest to optimize combination drug strategies for the management of advanced stage non-small-cell lung cancer

Page Widick, D. Costa, P. Bindal, 2020, Translational cancer research.

Can PD-L1 tumor proportion score be used as the key to unlocking the KEYNOTE studies of pembrolizumab in advanced lung cancer?

D. Costa, K. Sehgal, Deepa Rangachari, 2019, Translational lung cancer research.

From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung Cancer.

D. Costa, Deepa Rangachari, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.

S. Kobayashi, D. Costa, H. Reddi, 2017, Lung cancer.

De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancers.

D. Dias-Santagata, A. Majid, S. Kobayashi, 2016, Lung cancer.

Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches

D. Costa, D. Rangachari, M. Shea, 2016, Therapeutic advances in respiratory disease.

Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.

S. Kobayashi, D. Costa, S. Schulman, 2015, Lung cancer.

Lung Cancer with a High Tumor Mutational Burden.

D. Costa, P. VanderLaan, Deepa Rangachari, 2018, The New England journal of medicine.

PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?

D. Costa, P. VanderLaan, Vanda F Torous, 2018, Journal of the American Society of Cytopathology.

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3–PD‐L1 ≥50% Expression in Lung Adenocarcinoma

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire disease.

D. Costa, Deepa Rangachari, 2017, Translational cancer research.

A Veteran Presenting With Altered Mental Status and Clonus.

Anthony C Breu, D. Rangachari, B. Schlechter, 2020, Federal practitioner : for the health care professionals of the VA, DoD, and PHS.

Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non–Small-Cell Lung Cancer

M. Kris, C. Azzoli, J. Shrager, 2021, JCO precision oncology.

Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.

S. Kobayashi, V. Miller, D. Costa, 2015, Clinical lung cancer.

Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice.

A. Majid, D. Costa, X. Le, 2015, Cancer treatment communications.

Extended-Interval Dosing Strategy of Immune Checkpoint Inhibitors in Lung Cancer: Will it Outlast the COVID-19 Pandemic?

D. Costa, K. Sehgal, Deepa Rangachari, 2020, Frontiers in Oncology.

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer.

M. Lawrence, S. Digumarthy, M. Mino‐Kenudson, 2019, Cancer discovery.

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2018, Clinical Cancer Research.

When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?

S. Cannistra, N. Tung, K. DeLeonardis, 2019, Journal of oncology practice.

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

D. Costa, D. Rangachari, P. VanderLaan, 2018, Cancer treatment and research communications.

Clinical Benefit of Tyrosine Kinase Inhibitors in Advanced Lung Cancer with EGFR-G719A and Other Uncommon EGFR Mutations.

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2020, The oncologist.

Small cell transformation of non-small cell lung cancer on immune checkpoint inhibitors: uncommon or under-recognized?

D. Costa, P. VanderLaan, A. Varkaris, 2020, Journal for immunotherapy of cancer.

Safety and Efficacy of PD‐1 Inhibitors Among HIV‐Positive Patients With Non–Small Cell Lung Cancer

D. Costa, F. Marty, M. Cheng, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.

D. Costa, X. Le, D. Rangachari, 2017, Journal of thoracic disease.

Association of Performance Status With Survival in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy

Page Widick, D. Costa, R. Gill, 2021, JAMA network open.

Extensive-Stage Small-Cell Lung Cancer With Sustained Complete Response to Single-Agent Nivolumab and Immune-Related Dermatitis.

Page Widick, D. Costa, R. Gill, 2019, Clinical lung cancer.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

D. Rangachari, R. Patell, R. Hallowell, 2019, Respiratory medicine case reports.

Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.

D. Costa, F. Marty, M. Awad, 2020, Lung cancer.

Targeting the Immune System in the Treatment of Non-Small-Cell Lung Cancer

J. Brahmer, Deepa Rangachari, 2013, Current Treatment Options in Oncology.

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers.

D. Costa, E. Wong, E. Uhlmann, 2015, Lung cancer.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy.

S. Kobayashi, D. Costa, X. Le, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Quiz page January 2014: Cachexia, urinary tract infection, nephromegaly, and kidney failure.

B. Bhasin, C. Sperati, A. Storm, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.

D. Costa, D. Rangachari, A. Varkaris, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oncology Fellows' Clinical Discussions, Perceived Knowledge, and Formal Training Regarding Medical Cannabis Use: A National Survey Study

M. Schonberg, I. Braun, M. Buss, 2022, JCO oncology practice.

Brief Report: EGFR-mutated lung cancers resistant to osimertinib through EGFR-C797S respond to 1st generation reversible EGFR inhibitors but eventually acquire EGFR-T790M/C797S in preclinical models and clinical samples.

C. Paweletz, P. Jänne, S. Kobayashi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Acquired Resistance to Osimertinib Plus Savolitinib Is Mediated by MET-D1228 and MET-Y1230 Mutations in EGFR-Mutated MET-Amplified Lung Cancer

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2020, JTO Clinical and Research Reports.

Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancer.

J. Aronovitz, Page Widick, D. Costa, 2022, Lung cancer.

Clinical coaching: Evolving the apprenticeship model for modern housestaff

L. Brown, D. Kern, D. Rangachari, 2017, Medical teacher.

Targeting ROS1 rearrangements in non-small cell lung cancer with crizotinib and other kinase inhibitors.

D. Costa, D. Rangachari, R. Patell, 2018, Translational cancer research.

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase Inhibitors

S. Kobayashi, D. Costa, M. Fujii, 2020, JTO clinical and research reports.

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?

D. Costa, Adeela Khan, K. Sehgal, 2020, Precision cancer medicine.

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-Review.

D. Costa, Y. Sheikine, E. Folch, 2016, Clinical lung cancer.

Tumor biomarker testing in non-small-cell lung cancer: A decade of change.

Adnan Majid, A. Majid, S. Kobayashi, 2018, Lung cancer.

Molecular Testing Turnaround Time for Non-Small Cell Lung Cancer in Routine Clinical Practice Confirms Feasibility of CAP/IASLC/AMP Guideline Recommendations: A Single-center Analysis.

D. Costa, P. VanderLaan, Yael K. Heher, 2017, Clinical lung cancer.

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice.

D. Costa, E. Folch, D. Rangachari, 2016, Cancer treatment communications.

De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.

A. Majid, D. Costa, X. Le, 2015, Lung cancer.

Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.

S. Kobayashi, D. Costa, D. Rangachari, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors.

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2023, Lung cancer.

The rapidly evolving landscape of biomarker testing in non–small cell lung cancer

D. Costa, D. Rangachari, P. VanderLaan, 2020, Cancer cytopathology.

EGFR-D770>GY and Other Rare EGFR Exon 20 Insertion Mutations with a G770 Equivalence Are Sensitive to Dacomitinib or Afatinib and Responsive to EGFR Exon 20 Insertion Mutant-Active Inhibitors in Preclinical Models and Clinical Scenarios

S. Kobayashi, D. Costa, Susumu S. Kobayashi, 2021, Cells.

Correction: EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, S. Kobayashi, D. Costa, 2020, Clinical Cancer Research.

Twelve tips for teaching oncology to non-oncologists

A. Hale, Daniel N. Ricotta, J. Freed, 2020, Medical teacher.

Identification of a RAS-activating TMEM87A–RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non–Small Cell Lung Cancer

P. Jänne, D. Costa, N. Wagle, 2020, Clinical Cancer Research.

Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future

C. Lathan, Daniel A Roberts, J. Faig, 2022, JCO oncology practice.

Moving From Theory to Practice in Oncology Education When Virtual Is Your Reality.

A. Im, Sam Brondfield, D. Rangachari, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

De novo ERBB2 amplification causing intrinsic resistance to erlotinib in EGFR-L858R mutated TKI-naïve lung adenocarcinoma.

D. Costa, Siraj M. Ali, K. Gowen, 2017, Lung cancer.

EGFR -mutated lung cancers resistant to osimertinib through EGFR -C797S respond to 1 st generation reversible EGFR inhibitors but eventually acquire EGFR -T790M/C797S in preclinical models and clinical samples

C. Paweletz, P. Jänne, S. Kobayashi, 2019 .

Integrating Palliative Care in Oncology: The Oncologist as a Primary Palliative Care Provider

Thomas J. Smith, Deepa Rangachari, 2013, Cancer journal.

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates

D. Costa, Susumu S. Kobayashi, P. VanderLaan, 2023, Translational lung cancer research.

Concurrent osimertinib plus gefitinib for first-line treatment of EGFR-mutated non-small cell lung cancer (NSCLC).

C. Paweletz, P. Jänne, D. Costa, 2020 .

Fishing for Precision in ALK-Rearranged Non-Small-Cell Lung Cancers

D. Costa, X. Le, M. L. Peters, 2015 .

EGFR Exon 20 Insertion Mutations Display Sensitivity to Hsp90 Inhibition in Preclinical Models and Lung Adenocarcinomas

L. Sequist, D. Costa, G. Oxnard, 2018, Clinical Cancer Research.

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.

D. Costa, D. Rangachari, M. L. Peters, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC

D. Costa, N. Rizvi, K. Kehl, 2020, JTO clinical and research reports.

Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

D. Costa, G. Weiss, R. Gill, 2020, Clinical Lung Cancer.

EGFR-A763_Y764insFQEA: A unique exon 20 insertion mutation that displays sensitivity to all classes of approved lung cancer EGFR tyrosine kinase inhibitors.

D. Costa, Susumu S. Kobayashi, P. VanderLaan, 2019, Journal of Clinical Oncology.